Analysts predict a 56% YoY growth for the company to break e...
Analysts predict a 56% YoY growth for the company to break even by 2026, an extremely optimistic outlook. Slower growth will delay profitability. The company's debt-free status, unusual for a loss-making biotech, lowers investment risk.
When Will Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Become Profitable?
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment